1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Microbial Fermentation Technology Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Microbial Fermentation Technology Market Analysis and Forecast, 2022-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry
6. Microbial Fermentation Technology Market Analysis and Forecast, by Product
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Medical
6.3.1.1. Antibiotics
6.3.1.2. Probiotics
6.3.1.3. Monoclonal Antibodies
6.3.1.4. Recombinant Proteins
6.3.1.5. Other Biosimilars
6.3.2. Industrial
6.3.2.1. Acetone, Ethanol & Butanol
6.3.2.2. Enzymes & Amino Acids
6.3.3. Alcoholic Beverages
6.3.3.1. Beer
6.3.3.2. Spirits
6.3.3.3. Wine
6.3.3.4. Others
6.3.4. Food & Feed Products
6.4. Market Attractiveness, by Product
7. Global Microbial Fermentation Technology Market Analysis and Forecast, by End-user Industry
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user Industry, 2017–2031
7.3.1. Biopharmaceutical
7.3.2. Food & Feed
7.3.3. Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs)
7.3.4. Academic Research Institutes
7.3.5. Others
7.4. Market Attractiveness, by End-user Industry
8. Global Microbial Fermentation Technology Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Microbial Fermentation Technology Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product, 2022–2031
9.2.1. Medical
9.2.1.1. Antibiotics
9.2.1.2. Probiotics
9.2.1.3. Monoclonal Antibodies
9.2.1.4. Recombinant Proteins
9.2.1.5. Other Biosimilars
9.2.2. Industrial
9.2.2.1. Acetone, Ethanol & Butanol
9.2.2.2. Enzymes & Amino Acids
9.2.3. Alcoholic Beverages
9.2.3.1. Beer
9.2.3.2. Spirits
9.2.3.3. Wine
9.2.3.4. Others
9.2.4. Food & Feed Products
9.3. Market Value Forecast, by End-user Industry, 2022–2031
9.3.1. Biopharmaceutical
9.3.2. Food & Feed
9.3.3. Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs)
9.3.4. Academic Research Institutes
9.3.5. Others
9.4. Market Value Forecast, by Country, 2022–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By End-user Industry
9.5.3. By Country
10. Europe Microbial Fermentation Technology Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2022–2031
10.2.1. Medical
10.2.1.1. Antibiotics
10.2.1.2. Probiotics
10.2.1.3. Monoclonal Antibodies
10.2.1.4. Recombinant Proteins
10.2.1.5. Other Biosimilars
10.2.2. Industrial
10.2.2.1. Acetone, Ethanol & Butanol
10.2.2.2. Enzymes & Amino Acids
10.2.3. Alcoholic Beverages
10.2.3.1. Beer
10.2.3.2. Spirits
10.2.3.3. Wine
10.2.3.4. Others
10.2.4. Food & Feed Products
10.3. Market Value Forecast, by End-user Industry, 2022–2031
10.3.1. Biopharmaceutical
10.3.2. Food & Feed
10.3.3. Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs)
10.3.4. Academic Research Institutes
10.3.5. Others
10.4. Market Value Forecast, by Country/Sub-region, 2022–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By End-user Industry
10.5.3. By Country/Sub-region
11. Asia Pacific Microbial Fermentation Technology Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2022–2031
11.2.1. Medical
11.2.1.1. Antibiotics
11.2.1.2. Probiotics
11.2.1.3. Monoclonal Antibodies
11.2.1.4. Recombinant Proteins
11.2.1.5. Other Biosimilars
11.2.2. Industrial
11.2.2.1. Acetone, Ethanol & Butanol
11.2.2.2. Enzymes & Amino Acids
11.2.3. Alcoholic Beverages
11.2.3.1. Beer
11.2.3.2. Spirits
11.2.3.3. Wine
11.2.3.4. Others
11.2.4. Food & Feed Products
11.3. Market Value Forecast, by End-user Industry, 2022–2031
11.3.1. Biopharmaceutical
11.3.2. Food & Feed
11.3.3. Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs)
11.3.4. Academic Research Institutes
11.3.5. Others
11.4. Market Value Forecast, by Country/Sub-region, 2022–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By End-user Industry
11.5.3. By Country/Sub-region
12. Latin America Microbial Fermentation Technology Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2022–2031
12.2.1. Medical
12.2.1.1. Antibiotics
12.2.1.2. Probiotics
12.2.1.3. Monoclonal Antibodies
12.2.1.4. Recombinant Proteins
12.2.1.5. Other Biosimilars
12.2.2. Industrial
12.2.2.1. Acetone, Ethanol & Butanol
12.2.2.2. Enzymes & Amino Acids
12.2.3. Alcoholic Beverages
12.2.3.1. Beer
12.2.3.2. Spirits
12.2.3.3. Wine
12.2.3.4. Others
12.2.4. Food & Feed Products
12.3. Market Value Forecast, by End-user Industry, 2022–2031
12.3.1. Biopharmaceutical
12.3.2. Food & Feed
12.3.3. Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs)
12.3.4. Academic Research Institutes
12.3.5. Others
12.4. Market Value Forecast, by Country/Sub-region, 2022–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By End-user Industry
12.5.3. By Country/Sub-region
13. Middle East & Africa Microbial Fermentation Technology Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2022–2031
13.2.1. Medical
13.2.1.1. Antibiotics
13.2.1.2. Probiotics
13.2.1.3. Monoclonal Antibodies
13.2.1.4. Recombinant Proteins
13.2.1.5. Other Biosimilars
13.2.2. Industrial
13.2.2.1. Acetone, Ethanol & Butanol
13.2.2.2. Enzymes & Amino Acids
13.2.3. Alcoholic Beverages
13.2.3.1. Beer
13.2.3.2. Spirits
13.2.3.3. Wine
13.2.3.4. Others
13.2.4. Food & Feed Products
13.3. Market Value Forecast, by End-user Industry, 2022–2031
13.3.1. Biopharmaceutical
13.3.2. Food & Feed
13.3.3. Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs)
13.3.4. Academic Research Institutes
13.3.5. Others
13.4. Market Value Forecast, by Country/Sub-region, 2022–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By End-user Industry
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Biocon
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Danone Limited
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Lonza
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. United Breweries Ltd.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Amyris
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Novozymes
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. TerraVia Holdings, Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. BioVectra
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. DSM
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. F. Hoffmann La-Roche Ltd.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/